Heritable one-hit events defining cancer prevention?

Cell Cycle

Volumn 12, Issue 16, 2013, Pages 2553-2557

  Kopelovich, Levy ^a,d   Shea Herbert, Brittney ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer prevention; Cancer syndromes; Driver mutations; Knudson; One hit; Passenger mutations; Two hit

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ARTICLE; AUTOSOMAL DOMINANT DISORDER; BASAL CELL CARCINOMA; BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CELL TRANSFORMATION; CHROMOSOME ABERRATION; COLON CANCER; COLORECTAL CANCER; COWDEN SYNDROME; DRIVER MUTATION; EPIGENETICS; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HERITABILITY; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NON MELANOMA SKIN CANCER; ONCOGENE; ONE HIT MUTATION; OVARY CANCER; PASSENGER MUTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PROTO ONCOGENE; RHABDOMYOSARCOMA; SKIN FIBROBLAST; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; TWO HIT MUTATION; VIRUS ONCOGENE;

CANCER PREVENTION; CANCER SYNDROMES; DRIVER MUTATIONS; KNUDSON; ONE-HIT; PASSENGER MUTATIONS; TWO-HIT;

CARCINOGENESIS; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INHERITANCE PATTERNS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS;

EID: 84883220499     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25690     Document Type: Article

References (44)

1. Balmain A. Cancer genetics: from Boveri and Mendel to microarrays. Nat Rev Cancer 2001; 1:77-82; PMID:11900254; http://dx.doi.org/10.1038/35094086
2. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009; 10:478-87; PMID:19546858; http://dx.doi.org/10.1038/nrm2718
3. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820-3; PMID:5279523; http://dx.doi.org/10. 1073/pnas.68.4.820
4. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science 2013; 339:1546-58; PMID:23539594; http://dx.doi.org/10.1126/science.1235122
5. Knudson AG Jr. Heredity and human cancer. Am J Pathol 1974; 77:77-84; PMID:4447124
6. Kinzler KW, Vogelstein B. Introduction to human genetics, Chapter 4; cancer. In: The online metabolic and molecular bases of inherited disease Vallie D., editor-in chief, The McGraw Hill publishers London, 2013.
7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6:963-8; PMID:13094644; http://dx.doi.org/10.1002/1097-0142(195309) 6:5963::AIDCNCR2820060515 3.0.CO;2-Q
8. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139:871-90; PMID:19945376; http://dx.doi.org/10.1016/j.cell.2009.11.007
9. Nistico P, Bissell MJ, Radisky DC. Epithelial Mesenchymal Transision: General Priciples and pathological relevance with special emphasius on the role of martrix metalloproteinases CSH perspective in biol. 2012; 4: aO 11908
10. Kopelovich L, Henson DE, Gazdar AF, Dunn B, Srivastava S, Kelloff GJ, et al. Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect. Clin Cancer Res 1999; 5:3899-905; PMID:10632318
11. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71:747-52; PMID:5360287; http://dx.doi.org/10.7326/0003-4819-71-4-747
12. Li FP, Fraumeni JF Jr., Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358-62; PMID:3409256
13. Malkin D, Li FP, Strong LC, Fraumeni JF Jr., Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-8; PMID:1978757; http://dx.doi.org/10. 1126/science.1978757
14. Levine AJ, Greenbaum B. The maintenance of epigenetic states by p53: the guardian of the epigenome. Oncotarget 2012; 3:1503-4; PMID:23237909
15. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266:120-2; PMID:7939630; http://dx.doi.org/10.1126/science.7939630
16. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71; PMID:7545954; http://dx.doi.org/10.1126/ science.7545954
17. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12:333-7; PMID:8589730; http://dx.doi.org/10.1038/ ng0396-333
18. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-92; PMID:8524414; http://dx.doi.org/10.1038/378789a0
19. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003; 22:183-98; PMID:12938083; http://dx.doi.org/10.1002/humu.10257
20. Kopelovich L. Adenomatosis of the colon and rectum: Relevance to hereditary and susceptibility mechanisms. Cancer Surv 1982; 1:72-81
21. Yeung AT, Patel BB, Li XM, Seeholzer SH, Coudry RA, Cooper HS, et al. One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res 2008; 68:7579-86; PMID:18794146; http://dx.doi.org/10.1158/0008-5472.CAN-08-0856
22. Patel BB, Li XM, Dixon MP, Blagoi EL, Nicolas E, Seeholzer SH, et al. APC +/-alters colonic fibroblast proteome in FAP. Oncotarget 2011; 2:197-208; PMID:21411865
23. Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, et al. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther 2004; 3:1313-21; PMID:15662135; http://dx.doi.org/10.4161/cbt.3.12.1459
24. Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, et al. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) 2010; 3:48-61; PMID:20051372; http://dx.doi.org/10.1158/1940-6207.CAPR-09-0078
25. Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, et al. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 2010; 1:405-22; PMID:21311097
26. Fan M, Pfeffer SR, Lynch HT, Cassidy P, Leachman S, Pfeffer LM, Kopelovich L. Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: relevance to early intervention. Oncotarget 2013; 4:128-41; PMID:23371019
27. Hardy JD. The ubiquitous fibroblast. Multiple oncogenic potentials with illustrative cases. Ann Surg 1987; 205:445-55; PMID:3034175; http://dx.doi.org/10.1097/00000658-198705000-00002
28. Kopelovich L. Heritable colorectal cancer and cancer genes: systemic expressions. Mol Carcinog 1993; 8:3-6; PMID:8352889; http://dx.doi.org/10.1002/ mc.2940080104
29. Kopelovich L, DeLeo A. Fibroblasts from humans genetically predisposed to colon cancer show abnormal levels of the transformation-associated cellular p53 protein. J Natl Cancer lnst 1986; 77:1241-46
30. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 2009; 69:8175-82; PMID:19826045; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-1377
31. Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron AJ, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 2009; 69:2559-67; PMID:19276372; http://dx.doi.org/10.1158/0008-5472.CAN-08-2929
32. Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des 2011; 17:631-9; PMID:21391904; http://dx.doi.org/ 10.2174/138161211795222595
33. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55; PMID:22661227; http://dx.doi.org/10.1101/ gad.191999.112
34. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-63; PMID:22817889; http://dx.doi.org/10.1016/j.cell.2012.06.024
35. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003; 22:9217-24; PMID:14681681; http://dx.doi.org/10. 1038/sj.onc.1206909
36. Lynch HT, Fusaro RM, Lynch JF, Brand R. Pancreatic cancer and the FAMMM syndrome. Fam Cancer 2008; 7:103-12; PMID:17992582; http://dx.doi.org/10.1007/ s10689-007-9166-4
37. Pfeffer LM, Kopelovich L. Differential genetic susceptibility of cultured human skin fibroblasts to transformation by Kirsten murine sarcoma virus. Cell 1977; 10:313-20; PMID:189938; http://dx.doi.org/10.1016/0092-8674(77)90225-2
38. Kopelovich L, Demian SE. Phenotype modulation of human adult fibroblasts by oncogenes. Mol Carcinog 1996; 15:163-6; PMID:8597528; http://dx.doi.org/10. 1002/(S ICI)1098-2744(199603)15:3163::AID-MC13.0.CO;2-J
39. Okita K, Watanaby S. Induced pluripotent stem cells: opportumities and challenges. Philos. Trans. R Soc. London Biol. Sci. 2013; 366:198-207
40. Halley-Stott RP, Gurdon JB. Epigenetic memory in the context of nuclear reprogramming and cancer. Brief Funct Genomics 2013; 12:164-73; PMID:23585580; http://dx.doi.org/10.1093/bfgp/elt011
41. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64:235-48; PMID:1988146; http://dx.doi.org/10.1016/0092-8674(91)90636-D
42. Varrnus H. An historical overview of oncogenes. In: Weinberg RA (ed). Oncogenes and the Molecular Origins of Cancer. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 1989:3-44.
43. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49:3713-21, 2, 1; PMID:2660980
44. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012; 2:356-65; PMID:22576212; http://dx.doi.org/10.1158/2159-8290.CD-11-0241